Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

<h4>Background</h4>Roflumilast is the first phosphodiesterase-4 (PDE4) inhibitor to have been approved for the treatment of COPD. The anti-inflammatory profile of PDE4 inhibitors has not yet been explored in human lung tissues. We investigated the effects of roflumilast and its active me...

Full description

Bibliographic Details
Main Authors: Amparo Buenestado, Marie-Camille Chaumais, Stanislas Grassin-Delyle, Paul-André Risse, Emmanuel Naline, Elisabeth Longchampt, Hermann Tenor, Philippe Devillier
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24066150/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24066150/pdf/?tool=EBI

Similar Items